7.30

2.24% 0.16

After Hours: 7.24 -0.06 -0.82%

Immunitybio Inc (IBRX)

Overview News Price History Option Chain Financials Why IBRX Down? Discussions Forecast

Immunitybio Inc stock is traded at $7.30, with a volume of 14.05M. It is up +2.24% in the last 24 hours and down -30.08% over the past month. ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Previous Close:

$7.14

Open:

$6.89

24h Volume:

14.05M

Relative Volume:

0.38

Market Cap:

$7.54B

Revenue:

$113.29M

Net Income/Loss:

$-351.47M

P/E Ratio:

-18.73

EPS:

-0.3898

Net Cash Flow:

$-309.19M

1W Performance:

-1.08%

1M Performance:

-30.08%

6M Performance:

+192.00%

1Y Performance:

+139.34%

1-Day Range:

$6.88

$7.35

1-Week Range:

$6.57

$7.85

52-Week Range:

$1.83

$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Name

Immunitybio Inc

Sector

Healthcare (1118)

Industry

Biotechnology (624)

Phone

(844) 696-5235

Address

3530 JOHN HOPKINS COURT, SAN DIEGO

Employee

691

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IBRX Immunitybio Inc	7.30	7.54B	113.29M	-351.47M	-309.19M	-0.3898
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight
Mar-06-25	Initiated	H.C. Wainwright	Buy
Jan-10-25	Initiated	BTIG Research	Buy
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-03-22	Initiated	Jefferies	Buy

View All

Immunitybio Inc Stock (IBRX) Latest News

Apr 05, 2026

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald

Apr 05, 2026

Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio - Oncodaily

Apr 05, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer

Apr 05, 2026

CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Downgrade) - Seeking Alpha

Apr 05, 2026

Apr 04, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 04, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire

Apr 04, 2026

ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up - TipRanks

Apr 04, 2026

IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire

Apr 04, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com

Apr 04, 2026

Investors with Substantial Losses in ImmunityBio (IBRX) Have Opportunity to Lead Class Action Lawsuit - National Today

Apr 04, 2026

Apr 03, 2026

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

Apr 03, 2026

IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire

Apr 03, 2026

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire

Apr 03, 2026

Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - Carroll County Mirror-Democrat

Apr 03, 2026

When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio - Medical Marketing and Media

Apr 03, 2026

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Apr 03, 2026

NYSE: PINS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Pinterest, Inc. - GlobeNewswire Inc.

Apr 03, 2026